Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 41

Sort by

Sort Order Select

Journal Articles

Vincristine-Induced Peripheral Neuropathy in Pediatric Oncology Patients Receiving Vincristine through Push Injections or One-Hour Infusions: Results of a Randomized Clinical Trial

Mirjam Esther Van De Velde, MD, Gertjan Johannes Laurentius Kaspers, Prof. MD PhD, Floor Abbink, MD, Marry M. van den Heuvel-Eibrink, Prof, MD PhD, Cor van den Bos, MD PhD, Inge M. van der Sluis, MD PhD, Heidi Segers, MD PhD, Leen Willems, MD PhD, Jutte Van Der Werff, Prof, MD PhD, Christophe Chantrain, MD PhD, Machteld Heleen van den Berg, PhD

Blood (2019) 134 (Supplement_1): 1350.

https://doi.org/10.1182/blood-2019-126532

Published: 2019

Journal Articles

Phase 2 Study of Frontline Brentuximab Vedotin Plus Nivolumab in Patients with Hodgkin Lymphoma Aged ≥60 Years

Christopher A. Yasenchak, MD, Rodolfo Bordoni, MD, Victor Yazbeck, MD, Dipti Patel-Donnelly, MD, Thomas Anderson, Timothy Larson, MD, Trevor Newhook, MS, Matthew Mei, MD, Linda Ho, Jonathan W. Friedberg, MD

Blood (2019) 134 (Supplement_1): 237.

https://doi.org/10.1182/blood-2019-124866

Published: 2019

Journal Articles

Bing Neel Syndrome: Retrospective Australasian Experience of a Rare Treatable Complication of Waldenström Macroglobulinaemia/ Lymphoplasmacytic Lymphoma

Dipti Talaulikar, PhD FRACP, FRCPA, MBBS, Tara Cochrane, MBBS, John Gibson, Nada Hamad, MBBS, BSc, MSc, Phoebe Joy Ho, MBBS DPhil FRACP FRCPA, Samar Issa, FRACP, Kwok Fiona, Jun Hee Lim, PhD, David Simpson, MBChB, FRACP, FRCPA, Constantine Tam, MD PhD, Jorge J. Castillo, MD

Blood (2018) 132 (Supplement 1): 5325.

https://doi.org/10.1182/blood-2018-99-113969

Published: 2018

Journal Articles

Vincristine Induced Peripheral Neuropathy: A Randomized Controlled Trial Comparing Bolus Injections with One Hour Infusions during Induction in a Pediatric Population of Acute Lymphoblastic Leukemia and Hodgkin's Lymphoma

Mirjam Esther Velde, MD MSc, Machteld Heleen van den Berg, PhD, Floor Abbink, MD, Heidi Segers, MD PhD, Barbara De Moerloose, MD PhD, Marry M. van den Heuvel-Eibrink, Prof, Cor van den Bos, MD PhD, Inge M. van der Sluis, MD PhD, Gertjan Johannes Laurentius Kaspers, MD PhD

Blood (2018) 132 (Supplement 1): 5200.

https://doi.org/10.1182/blood-2018-99-115905

Published: 2018

Journal Articles

Brentuximab Vedotin with R-CHP Chemotherapy As Frontline Treatment for Patients with CD30 Positive Primary Mediastinal Large B-Cell, Diffuse Large B-Cell, and Grey Zone Lymphomas: Results of a Phase I/II Multisite Trial

Jakub Svoboda, MD, Daniel J. Landsburg, MD, Sunita Dwivedy Nasta, MD, Stefan Klaus Barta, MDMRCP,MS, Nadia Khan, MD, Henry C. Fung, FRCP,MBBChir, Carlyn Rose Tan, MD, Joanne Filicko-O'Hara, MD, Sameh Gaballa, MD, Lauren Elizabeth Strelec, BA, Sarah J. Nagle, Steven M. Bair, MD, Sheryl Mitnick, MPH, RN, Terease S. Waite, PhD RN, MBE, Rachel Lynn Sargent, MD, Agata M. Bogusz, MDPhD, Ziver Sahin, MD, Anthony R. Mato, MD, Stephen J. Schuster, MD

Blood (2017) 130 (Supplement 1): 191.

https://doi.org/10.1182/blood.V130.Suppl_1.191.191

Published: 2017

Journal Articles

Results of an Ongoing Phase 2 Study of Brentuximab Vedotin with Rchp As Frontline Therapy in Patients with High-Intermediate/High-Risk Diffuse Large B Cell Lymphoma (DLBCL)

Blood (2016) 128 (22): 104.

https://doi.org/10.1182/blood.V128.22.104.104

Published: 2016

Journal Articles

Polatuzumab Vedotin Combined with Bendamustine (B) and Rituximab (R) or Obinutuzumab (G) in Patients with Relapsed or Refractory (R/R) Follicular Lymphoma (FL) or Diffuse Large B-Cell Lymphoma (DLBCL): Preliminary Results of a Phase Ib/II Dose-Escalation Study

Alex F Herrera, MD, Matthew J. Matasar, MD MS, Sarit Assouline, Manali Kamdar, MD, Amitkumar Mehta, MD, Isabelle Fleury, MD, Won Seog Kim, Tae Min Kim, MD PhD, Francesc Bosch, MD PhD, John A Radford, MBChB, MRCP, MD FRCP, Lilian Bu, MS, Wan-Jen Hong, MD, Laurie H Sehn, MD

Blood (2016) 128 (22): 4194.

https://doi.org/10.1182/blood.V128.22.4194.4194

Published: 2016

Journal Articles

Long-Term Responders after Brentuximab Vedotin: Experience on 57 Patients with Relapsed and Refractory Hodgkin and Anaplastic Large Cell Lymphoma

Pier Luigi Zinzani, MD PhD, Letizia Gandolfi, Beatrice Casadei, Cinzia Pellegrini, Alessandro Broccoli, MD, Enrico Derenzini, MD, Federica Quirini, Lorenzo Tonialini, Michele Cavo, MD, Lisa Argnani, Vittorio Stefoni

Blood (2015) 126 (23): 2725.

https://doi.org/10.1182/blood.V126.23.2725.2725

Published: 2015

Journal Articles

Initial Results of US Intergroup Trial of Response-Adapted Chemotherapy or Chemotherapy/Radiation Therapy Based on PET for Non-Bulky Stage I and II Hodgkin Lymphoma (HL) (CALGB/Alliance 50604)

David J. Straus, MD, Brandelyn Pitcher, MS, Lale Kostakoglu, MD MPH, John C Grecula, MD, Eric D. Hsi, MD, Heiko Schoder, MD, Sin-Ho Jung, PhD, Leslie L. Popplewell, MD, Julie E Chang, MD, Craig H Moskowitz, MD, Nina Wagner-Johnson, MD, John P. Leonard, MD, Jonathan W. Friedberg, MD MMSc, Brad S Kahl, MD, Bruce D. Cheson, MD, Nancy L. Bartlett, MD

Blood (2015) 126 (23): 578.

https://doi.org/10.1182/blood.V126.23.578.578

Published: 2015

Journal Articles

Interim Analysis of a Phase 2 Study of Bortezomib Plus Rituximab Maintenance Therapy in Patients with Mantle Cell Lymphoma Status Post Autologous Stem Cell Transplantation

Robert Chen, Joycelynne Palmer, PhD, Leona Holmberg, Jessica Alluin, Pritsana Chomchan, PhD, Leslie L. Popplewell, MD, Tanya Siddiqi, MD, Sandra H. Thomas, PhD, Kathryn Irenze, Auayporn P. Nademanee, MD, Ricardo Spielberger, MD, John J Rossi, Steven T. Rosen, MD, Larry W. Kwak, MD, Stephen J. Forman, MD

Blood (2015) 126 (23): 1961.

https://doi.org/10.1182/blood.V126.23.1961.1961

Published: 2015

Journal Articles

Updated Efficacy and Safety Data from the AETHERA Trial of Consolidation with Brentuximab Vedotin after Autologous Stem Cell Transplant (ASCT) in Hodgkin Lymphoma Patients at High Risk of Relapse

John Sweetenham, Jan Walewski, MDPhDProf, Auayporn P. Nademanee, MD, Tamas Masszi, Edward Agura, Jerzy Holowiecki, Muneer H. Abidi, MD, Andy I Chen, MD PhD, Patrick Stiff, Simonetta Viviani, MD, Angelo Michele Carella, Dzhelil Osmanov, Veronika Bachanova, MD, Anna Sureda, MD PhD, Dirk Huebner, Emily K Larsen, Naomi N Hunder, Craig H Moskowitz, MD

Blood (2015) 126 (23): 3172.

https://doi.org/10.1182/blood.V126.23.3172.3172

Published: 2015

Journal Articles

Final Results from a Phase 2 Study of Pracinostat in Combination with Azacitidine in Elderly Patients with Acute Myeloid Leukemia (AML)

Guillermo Garcia-Manero, MD, Ehab Atallah, MD, Samer K Khaled, MD, Martha Arellano, Mrinal M Patnaik, MBBS, Todd A Butler, Carla Ashby, Bruno C. Medeiros, MD

Blood (2015) 126 (23): 453.

https://doi.org/10.1182/blood.V126.23.453.453

Published: 2015

Journal Articles

Brentuximab Vedotin Monotherapy and in Combination with Dacarbazine in Frontline Treatment of Hodgkin Lymphoma in Patients Aged 60 Years and Above: Interim Results of a Phase 2 Study

Andres Forero-Torres, MD, Beata Holkova, MD, Jeff P. Sharman, MD, Jonathan W. Friedberg, MD, Maurice J. Berkowitz, MD, William Fintel, MD, Robert Chen, MD, Ralph V. Boccia, MD, Mansoor Saleh, MD, Neil Josephson, MD, Maria Corinna Palanca-Wessels, MD PhD, Christopher A. Yasenchak, MD

Blood (2014) 124 (21): 294.

https://doi.org/10.1182/blood.V124.21.294.294

Published: 2014

Journal Articles

Nelarabine in Combination with Etoposide and Cyclophosphamide Is Active in First Relapse of Childhood T-Acute Lymphocytic Leukemia (T-ALL) and T-Lymphoblastic Lymphoma (T-LL)

Blood (2014) 124 (21): 795.

https://doi.org/10.1182/blood.V124.21.795.795

Published: 2014

Journal Articles

The Aethera Trial: Results of a Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of Brentuximab Vedotin in the Treatment of Patients at Risk of Progression Following Autologous Stem Cell Transplant for Hodgkin Lymphoma

Craig H. Moskowitz, MD, Auayporn Nadamanee, MD, Tamas Masszi, MD PhD, Edward Agura, MD, Jerzy Holowiecki, MD PhD, Muneer H. Abidi, MD, Andy I Chen, MDPhD, Patrick J. Stiff, MD, Alessandro M. Gianni, MD, Angelo M. Carella, MD, Dzhelil Osmanov, MD, Veronika Bachanova, MD, John Sweetenham, MD, Anna Sureda, Dirk Huebner, MD, Emily K. Larsen, MS, Naomi N.H. Hunder, MD, Jan Walewski

Blood (2014) 124 (21): 673.

https://doi.org/10.1182/blood.V124.21.673.673

Published: 2014

Journal Articles

Nelarabine Alone or in Combination in High Risk Childhood / Adolescent and Young Adults (AYA) T- Cell Acute Lymphoblastic Leukemia

Benoit Brethon, MD, Laetitia Morel, MD, Arnaud Petit, MD PhD, Etienne Lengliné, MD, Aurelie Cuinet, MD, Genevieve Vaudre, Thierry Leblanc, MD, Marie-Dominique Tabone, MD, Guy Leverger, MD, Nicolas Boissel, MD PhD, André Baruchel, MD

Blood (2014) 124 (21): 3723.

https://doi.org/10.1182/blood.V124.21.3723.3723

Published: 2014

Journal Articles

Final Results Of a Phase I Study Of The Anti-CD79b Antibody-Drug Conjugate DCDS4501A In Relapsed Or Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (NHL)

Maria Corinna Palanca-Wessels, M.D., Ph.D., Gilles Andre Salles, MD, PhD, Myron S. Czuczman, MD, Sarit E. Assouline, MD, Ian W. Flinn, MD, PhD, Laurie H. Sehn, MD, Manish Patel, MD, Randeep Sangha, Herve Tilly, MD, Ranjana Advani, MD, Olivier Casasnovas, MD, Oliver W. Press, MD, PhD, Sreeni Yalamanchili, BSPharm, Robert Kahn, Dan Lu, Akiko Chai, MS, Yu-Waye Chu, Franck Morschhauser

Blood (2013) 122 (21): 4400.

https://doi.org/10.1182/blood.V122.21.4400.4400

Published: 2013

Journal Articles

Frontline-Treatment Of Acute Lymphoblastic Leukemia (ALL) In Older Adolescents and Young Adults (AYA) Using a Pediatric Regimen Is Feasible: Toxicity Results of the Prospective US Intergroup Trial C10403 (Alliance)

Blood (2013) 122 (21): 3903.

https://doi.org/10.1182/blood.V122.21.3903.3903

Published: 2013

Journal Articles

Vincristine Sulfate Liposomes Injection (VSLI, Marqibo): Interim Results From a Phase I Study in Children and Adolescents with Refractory Cancer

Nirali N Shah, MD, Melinda Merchant, MD, PhD, Diane Cole, Kelly Richards, RN, Cindy Delbrook, RN, Brigitte C Widemann, MD, Alan S Wayne, MD

Blood (2012) 120 (21): 1497.

https://doi.org/10.1182/blood.V120.21.1497.1497

Published: 2012

Journal Articles

Salvage Therapy with Bortezomib Plus Lenalidomide for Relapsed/Refractory Mantle Cell Lymphoma: Initial Results of a Phase II Trial (Alliance/CALGB 50501)

Vicki A. Morrison, MD, Sin-Ho Jung, PhD, Jeffrey Johnson, MS, Ann LaCasce, MD, Kristie A. Blum, MD, Nancy L. Bartlett, MD, Bruce D. Cheson, MD

Blood (2012) 120 (21): 3696.

https://doi.org/10.1182/blood.V120.21.3696.3696

Published: 2012

NARROW

Vincristine-Induced Peripheral Neuropathy in Pediatric Oncology Patients Receiving Vincristine through Push Injections or One-Hour Infusions: Results of a Randomized Clinical Trial

Phase 2 Study of Frontline Brentuximab Vedotin Plus Nivolumab in Patients with Hodgkin Lymphoma Aged ≥60 Years

Bing Neel Syndrome: Retrospective Australasian Experience of a Rare Treatable Complication of Waldenström Macroglobulinaemia/ Lymphoplasmacytic Lymphoma

Vincristine Induced Peripheral Neuropathy: A Randomized Controlled Trial Comparing Bolus Injections with One Hour Infusions during Induction in a Pediatric Population of Acute Lymphoblastic Leukemia and Hodgkin's Lymphoma

Brentuximab Vedotin with R-CHP Chemotherapy As Frontline Treatment for Patients with CD30 Positive Primary Mediastinal Large B-Cell, Diffuse Large B-Cell, and Grey Zone Lymphomas: Results of a Phase I/II Multisite Trial

Results of an Ongoing Phase 2 Study of Brentuximab Vedotin with Rchp As Frontline Therapy in Patients with High-Intermediate/High-Risk Diffuse Large B Cell Lymphoma (DLBCL)

Polatuzumab Vedotin Combined with Bendamustine (B) and Rituximab (R) or Obinutuzumab (G) in Patients with Relapsed or Refractory (R/R) Follicular Lymphoma (FL) or Diffuse Large B-Cell Lymphoma (DLBCL): Preliminary Results of a Phase Ib/II Dose-Escalation Study

Long-Term Responders after Brentuximab Vedotin: Experience on 57 Patients with Relapsed and Refractory Hodgkin and Anaplastic Large Cell Lymphoma

Initial Results of US Intergroup Trial of Response-Adapted Chemotherapy or Chemotherapy/Radiation Therapy Based on PET for Non-Bulky Stage I and II Hodgkin Lymphoma (HL) (CALGB/Alliance 50604)

Interim Analysis of a Phase 2 Study of Bortezomib Plus Rituximab Maintenance Therapy in Patients with Mantle Cell Lymphoma Status Post Autologous Stem Cell Transplantation

Updated Efficacy and Safety Data from the AETHERA Trial of Consolidation with Brentuximab Vedotin after Autologous Stem Cell Transplant (ASCT) in Hodgkin Lymphoma Patients at High Risk of Relapse

Final Results from a Phase 2 Study of Pracinostat in Combination with Azacitidine in Elderly Patients with Acute Myeloid Leukemia (AML)

Brentuximab Vedotin Monotherapy and in Combination with Dacarbazine in Frontline Treatment of Hodgkin Lymphoma in Patients Aged 60 Years and Above: Interim Results of a Phase 2 Study

Nelarabine in Combination with Etoposide and Cyclophosphamide Is Active in First Relapse of Childhood T-Acute Lymphocytic Leukemia (T-ALL) and T-Lymphoblastic Lymphoma (T-LL)

The Aethera Trial: Results of a Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of Brentuximab Vedotin in the Treatment of Patients at Risk of Progression Following Autologous Stem Cell Transplant for Hodgkin Lymphoma

Nelarabine Alone or in Combination in High Risk Childhood / Adolescent and Young Adults (AYA) T- Cell Acute Lymphoblastic Leukemia

Final Results Of a Phase I Study Of The Anti-CD79b Antibody-Drug Conjugate DCDS4501A In Relapsed Or Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (NHL)

Frontline-Treatment Of Acute Lymphoblastic Leukemia (ALL) In Older Adolescents and Young Adults (AYA) Using a Pediatric Regimen Is Feasible: Toxicity Results of the Prospective US Intergroup Trial C10403 (Alliance)

Vincristine Sulfate Liposomes Injection (VSLI, Marqibo): Interim Results From a Phase I Study in Children and Adolescents with Refractory Cancer

Salvage Therapy with Bortezomib Plus Lenalidomide for Relapsed/Refractory Mantle Cell Lymphoma: Initial Results of a Phase II Trial (Alliance/CALGB 50501)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only